Bio-Rad said this week that its third-quarter revenues rose just over 1 percent year-over-year excluding currency effects, buoyed by strong growth in its Life Science segment, which houses the company's PCR, electrophoresis, and sample prep technologies, among others.

In addition, in a conference call discussing the company's Q3 earnings, company officials responded to analysts' questions about Bio-Rad's recent acquisition of digital PCR startup QuantaLife, but provided few new details as it works to integrate QuantaLife's operations into its own.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.